Search

Your search keyword '"Langevitz P"' showing total 4,771 results
Start Over "Langevitz P"

Refine your results

more »

more »

more »

more »

more »

more »

more »
4,771 results on '"Langevitz P"'

1. Herpes vaccine, splenectomy, and thymectomy associated with autoimmune diseases and the kaleidoscope of autoimmunity.

Author

Lucas Hernández A, Shovman O, Langevitz P, and Shoenfeld Y

Subjects
Humans, Autoimmune Diseases immunology, Splenectomy, Thymectomy, Autoimmunity
Abstract

Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Published
2024
Full Text
View/download PDF

2. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

Author

Abdulla Watad, Gabriele De Marco, Hussein Mahajna, Amit Druyan, Mailam Eltity, Nizar Hijazi, Amir Haddad, Muna Elias, Devy Zisman, Mohammad E. Naffaa, Michal Brodavka, Yael Cohen, Arsalan Abu-Much, Muhanad Abu Elhija, Charlie Bridgewood, Pnina Langevitz, Joanna McLorinan, Nicola Luigi Bragazzi, Helena Marzo-Ortega, Merav Lidar, Cassandra Calabrese, Leonard Calabrese, Edward Vital, Yehuda Shoenfeld, Howard Amital, and Dennis McGonagle

Subjects
vaccine safety, COVID-19, mRNA-based vaccine, adenoviral vector-based vaccine, immune-mediated diseases, Medicine
Abstract

Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines is based on either TLR-7/8 or TLR-9 agonism, which is distinct from previous vaccines and is a common pathogenic mechanism in IMDs. Methods: We evaluated IMD flares or new disease onset within 28-days of SARS-CoV-2 vaccination at five large tertiary centres in countries with early vaccination adoption, three in Israel, one in UK, and one in USA. We assessed the pattern of disease expression in terms of autoimmune, autoinflammatory, or mixed disease phenotype and organ system affected. We also evaluated outcomes. Findings: 27 cases included 17 flares and 10 new onset IMDs. 23/27 received the BNT - 162b2 vaccine, 2/27 the mRNA-1273 and 2/27 the ChAdOx1 vaccines. The mean age was 54.4 ± 19.2 years and 55% of cases were female. Among the 27 cases, 21 (78%) had at least one underlying autoimmune/rheumatic disease prior the vaccination. Among those patients with a flare or activation, four episodes occurred after receiving the second-dose and in one patient they occurred both after the first and the second-dose. In those patients with a new onset disease, two occurred after the second-dose and in one patient occurred both after the first (new onset) and second-dose (flare). For either dose, IMDs occurred on average 4 days later. Of the cases, 20/27 (75%) were mild to moderate in severity. Over 80% of cases had excellent resolution of inflammatory features, mostly with the use of corticosteroid therapy. Other immune-mediated conditions included idiopathic pericarditis (n = 2), neurosarcoidosis with small fiber neuropathy (n = 1), demyelination (n = 1), and myasthenia gravis (n = 2). In 22 cases (81.5%), the insurgence of Adverse event following immunization (AEFI)/IMD could not be explained based on the drug received by the patient. In 23 cases (85.2%), AEFI development could not be explained based on the underlying disease/co-morbidities. Only in one case (3.7%), the timing window of the insurgence of the side effect was considered not compatible with the time from vaccine to flare. Interpretation: Despite the high population exposure in the regions served by these centers, IMDs flares or onset temporally-associated with SARS-CoV-2 vaccination appear rare. Most are moderate in severity and responsive to therapy although some severe flares occurred. Funding: none.

Published
2021
Full Text
View/download PDF

12. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

Author

Isenberg, David, Gordon, Caroline, Licu, Daiana, Copt, Samuel, Rossi, Claudia Pena, Wofsy, David, Babini, A, Lazaro, M, Lucero, E, Merono, C, Rillo, O, Spindler, A, Tate, G, Velasco Zamora, B, Bossingham, D, Littlejohn, G, Nicholls, D, Reeves, G, Rischmueller, M, Zamani, O, Sato, E, Scheinberg, M, Zerbini, C, Rashkov, R, Glasnovic, M, Martinovic-Kaliterna, D, Morovic-Vergles, J, Novak, S, Tegzova, D, Vavrincova, P, Amoura, Z, Carle, P, Hachulla, E, Jorgensen, C, Sibilia, J, Viallard, J, Braun, J, Hiepe, F, Kuhn, A, Lorenz, H, Schmidt, R, Schulze-Koops, H, Wacker, J, Settas, L, Mouli Veeravalli, S, Balbir-Gurman, A, Langevitz, P, Mevorach, D, Molad, Y, Bae, S, Cho, CS, Kim, HY, Suh, C, Andersone, D, Ziade, N, Baranauskaite, A, Stropuviene, S, Gun, S, Kong, N, Sulaiman, W, Ramos Remus, C, Saldate Alonso, C, Huizinga, T, Tak, P, van Paassen, P, Arroyo, C, Gomez, H, Perez, E, Ramiterre, E, Salido, E, Brzosko, M, Chudzik, D, Dyczek, A, Jeka, S, Sierakowski, S, Zdrojewski, Z, Barbarash, O, Ershova, O, Gordienko, A, Lomareva, N, Shvarts, Y, Sorotskaya, V, Vezikova, N, Yakushin, S, Bogic, M, Dimic, A, Damjanov, N, Petrovic, R, Stojanovic, L, Kalla, A, Louw, I, Nayiager, S, Reuter, H, Spargo, C, Whitelaw, D, Carbonell Abello, J, Fernandez Nebro, A, Gomez Reino, J, Lopez Longo, F, von Kempis, J, Huang, CM, Lan, JL, Lin, HY, Liou, LB, Bruce, I, Tahir, H, Abrahamovych, O, Dyadyk, O, Nikirenkov, Y, Rudyk, Y, Smiyan, S, Stanislavchuk, M, Ter-Vartanyan, S, Aranow, C, Askanase, A, Chakravarty, E, Chatham, W, Clark, M, Dhar, P, Dikranian, A, Fiechtner, J, Ginzler, E, Harmon, C, Knibbe, W, Lee, E, Lockshin, M, Luggen, M, Massarotti, E, Mitri, G, Peng, S, and Singer, N

Published
2015
Full Text
View/download PDF

13. The Homogeneous Multiplexed System-a New Method for Autoantibody Profile in Systemic Lupus Erythematosus

Author

Gisele Zandman-Goddard, Boris Gilburd, Ora Shovman, Miri Blank, Svetlana Berdichevski, Pnina Langevitz, and Yehuda Shoenfeld

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease leading to immunological aberrations and excessive multiple autoantibody production. The aim of this study was to investigate the prevalence of multiple autoantibodies in SLE patients utilizing the multiplex system method.

Published
2005
Full Text
View/download PDF

14. The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab.

Author

Tunitsky-Lifshitz Y, Maoz-Segal R, Niznik S, Shavit R, Haj Yahia S, Langevitz P, and Agmon-Levin N

Subjects
Female, Humans, Adult, Middle Aged, Male, COVID-19 Vaccines, BNT162 Vaccine, Treatment Outcome, Antibodies, Viral, Lupus Erythematosus, Systemic drug therapy, COVID-19
Abstract

Introduction: Over 95% of healthy subjects develop anti-COVID IgG antibodies after receiving two doses of BNT162b2 COVID-19 vaccine. In comparison, 20%-30% of SLE patients do not seroconvert following 1-2 doses of COVID vaccines, potentially due to immunosuppression. The aim of this study was to assess immunogenicity and safety of BNT vaccine in SLE patients treated with Belimumab and especially the yield of a booster third dose in this population., Methods: SLE patients treated with Belimumab in the Sheba Medical Center, Israel, were included in this study. All were recommended to receive the BNT vaccine according to national guidelines; and were advised to perform serologic tests after receiving second and third doses. Clinical data included demographics, SLE treatments, adverse effects to vaccines and SLEDAI scores performed 2 weeks before vaccinations and 6-12 weeks after receiving the second or third dose of the vaccine., Results: Our cohort included 17 patients, 14 (82.35%) females, median age 50 ± 14.2 years, and disease duration 12 ± 10.57 years. Belimumab therapy was given for a mean of 6 ± 2.5 years. Of them, 15/17 patients received 3-doses of BNT vaccine. Serologic assessment was performed for 10 patients, 7/10(70%) became seropositive following the second dose, while 2/3 patients seroconverted only after the third dose. Vaccinations were well tolerated with minimal adverse events and no disease flares. SLEDAI scores before and after vaccinations were 4 ± 3.8 and 4 ± 2.7 ( p = 0.69), respectively., Conclusions: Immunization with the BNT vaccine is efficacious and safe for SLE patients treated with Belimumab. Following the third dose of vaccine, immunogenicity among SLE patients mounted to 90%, thereby approximating the general healthy population. No SLE disease flares and/or significant adverse events were noted in our cohort. Assessment of seroconversion and consideration of subsequent boosters of COVID-vaccine should be considered in this group of patients.

Published
2023
Full Text
View/download PDF

48. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study

Author

Cutolo, Maurizio, Herrick, Ariane L., Distler, Oliver, Becker, Mike O., Beltran, Emma, Carpentier, Patrick, Ferri, Clodoveo, Inanç, Murat, Vlachoyiannopoulos, Panayiotis, Chadha‐Boreham, Harbajan, Cottreel, Emmanuelle, Pfister, Thomas, Rosenberg, Daniel, Torres, Juan V., Smith, Vanessa, Becker, Mike, Erlacher, L, Hirschl, M, Kiener, HP, Pilger, E, Smith, V, Blockmans, D, Wautrecht, J‐C, Becvár, R, Carpentier, P, Frances, C, Lok, C, Sparsa, A, Hachulla, E, Quere, I, Allanore, Y, Agard, C, Riemekasten, G, Hunzelmann, N, Stücker, M, Ahmadi‐Simab, K, Sunderkötter, C, Wohlrab, J, Müller‐Ladner, U, Schneider, M, Vlachoyianopoulos, P, Vassilopoulos, D, Drosos, A, Antonopoulos, A, Balbir‐Gurman, A, Langevitz, P, Rosner, I, Levy, Y, Cutolo, M, Bombardieri, S, Ferraccioli, G, Mazzuca, S, Grassi, W, Lunardi, C, Airó, P, Riccieri, V, Voskuyl, AE, Schuerwegh, A, Santos, L, Rodrigues, AC, Grilo, A, Amaral, MC, Román Ivorra, JA, Castellvi, I, Distler, O, Spertini, F, Müller, R, Inanç, M, Oksel, F, Turkcapar, N, Herrick, A, Denton, C, McHugh, N, Chattopadhyay, C, Hall, F, Buch, M, University of Zurich, and Cutolo, Maurizio

Subjects
0301 basic medicine, Male, EUSTAR DATABASE, Settore MED/16 - REUMATOLOGIA, RAYNAUDS-PHENOMENON, PREDICTION, 2745 Rheumatology, Logistic regression, Microscopic Angioscopy, Cohort Studies, 0302 clinical medicine, Risk Factors, Medicine and Health Sciences, Immunology and Allergy, Prospective Studies, Prospective cohort study, digital ulcers, systemic sclerosis, nailfold capillaroscopy, Peripheral Vascular Diseases, Digital Ulcers, 10051 Rheumatology Clinic and Institute of Physical Medicine, Area under the curve, VASCULAR-DISEASE, Middle Aged, MICROVASCULAR DAMAGE, 2723 Immunology and Allergy, digital ulcers, Rheumatology, Immunology, Female, medicine.symptom, SEVERE ORGAN INVOLVEMENT, Cohort study, Adult, PULMONARY ARTERIAL-HYPERTENSION, medicine.medical_specialty, nailfold capillaroscopy, 610 Medicine & health, CAPILLAROSCOPIC ANALYSIS, Systemic Sclerosis, Fingers, 03 medical and health sciences, Videocapillaroscopy, Digital Ulcers, Systemic Sclerosis, Scleroderma, Limited, Internal medicine, Skin Ulcer, medicine, Humans, Videocapillaroscopy, Aged, 030203 arthritis & rheumatology, 2403 Immunology, Scleroderma, Systemic, ENDOTHELIN RECEPTOR ANTAGONIST, Receiver operating characteristic, business.industry, Skin ulcer, Confidence interval, Surgery, 030104 developmental biology, ROC Curve, Observational study, EULAR SCLERODERMA TRIALS, business
Abstract

Objective To identify nailfold videocapillaroscopic features and other clinical risk factors for new digital ulcers (DUs) during a 6-month period in patients with systemic sclerosis (SSc). Methods In this multicenter, prospective, observational cohort study, the videoCAPillaroscopy (CAP) study, we evaluated 623 patients with SSc from 59 centers (14 countries). Patients were stratified into 2 groups: a DU history group and a no DU history group. At enrollment, patients underwent detailed nailfold videocapillaroscopic evaluation and assessment of demographic characteristics, DU status, and clinical and SSc characteristics. Risk factors for developing new DUs were assessed using univariable and multivariable logistic regression (MLR) analyses. Results Of the 468 patients in the DU history group (mean ± SD age 54.0 ± 13.7 years), 79.5% were female, 59.8% had limited cutaneous SSc, and 22% developed a new DU during follow-up. The strongest risk factors for new DUs identified by MLR in the DU history group included the mean number of capillaries per millimeter in the middle finger of the dominant hand, the number of DUs (categorized as 0, 1, 2, or ≥3), and the presence of critical digital ischemia. The receiver operating characteristic (ROC) of the area under the curve (AUC) of the final MLR model was 0.738 (95% confidence interval [95% CI] 0.681–0.795). Internal validation through bootstrap generated a ROC AUC of 0.633 (95% CI 0.510–0.756). Conclusion This international prospective study, which included detailed nailfold videocapillaroscopic evaluation and extensive clinical characterization of patients with SSc, identified the mean number of capillaries per millimeter in the middle finger of the dominant hand, the number of DUs at enrollment, and the presence of critical digital ischemia at enrollment as risk factors for the development of new DUs.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results